We aimed to establish whether the expression of microRNA-34a (miR-34a) is correlated with that of c-MET and G1 phase regulators such as cyclin dependent kinase (CDK) 4, CDK6, and cyclin D (CCND) 1 in non-small cell lung cancer (NSCLC), and whether a relationship exists between miR-34a expression and both clinicopathologic factors and recurrence-free survival (RFS). For 58 samples archived from NSCLC patients, we measured the expression of miR-34a and c-MET, CDK4/6, and CCND1 by quantitative RT-PCR and assessed the relationship between miR-34a expression, clinicopathological factors, and RFS. The expression of miR-34a was significantly lower in squamous cell tumors (P < 0.001) and in tumors associated with lymphatic invasion (P = 0.001). We found significant inverse correlations between miR-34a and c-MET (R = -0.316, P = 0.028) and CDK6 expression (R = -0.4582, P = 0.004). RFS were longer in adenocarcinoma patients with high miR-34a expression than in those with low miR-34a expression (55.6 vs. 21.6 months; P = 0.020). With univariate analysis, statistically significant prognostic factors for RFS in adenocarcinoma patients were miR-34a expression (Relative risk (RR), 8.14; P = 0.049), TNM stage (RR, 13.55; P = 0.001), LN metastasis (RR, 4.19; P = 0.043), and the presence of lymphatic invasion (RR, 7.05; P = 0.015). In multivariate analysis, only miR-34a was prognostic for RFS (RR, 11.5; P = 0.027). miR-34a expression was inversely correlated with that of c-MET and CDK6 in NSCLC, and had prognostic significance for RFS, especially in adenocarcinoma patients.
Background: The microRNA(miR)s affect all aspects of cellular physiology including proliferation, apoptosis, development, aging, and metabolism. miR-34a has tumor suppressive role in various human cancers including non-small cell lung cancer (NSCLC). Recently, various targets of miR-34a including c-MET and G1-phase regulators have been reported in NSCLC cell lines. The aim of this study is to determine whether miR-34a is correlated with c-MET and G1 phase regulators such as cyclin dependent kinase (CDK) 4, CDK6 and cyclin D (CCND)1 in human NSCLC and assess the correlation between miR-34a and clinicopathologic characteristics and recurrence free survival (RFS). Material and Methods: In fresh frozen, paired tumor/normal adjacent tissue samples from 58 NSCLC patients underwent curative resection, expressions of miR-34a and c-MET, CDK4/6, and CCND1 were investigated by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis. Results: There was inverse correlation between miR-34a and c-MET (R = -0.316; P = 0.003) and CDK6 (R = -0.4582; P = 0.004), however, neither CDK4 (P = 0.556) nor CCND1 (P = 0.143). Of 14 patients with low miR-34a, the patients showing high expression of c-MET protein were 12 (85.7%), whereas, in 5 patients with high miR-34a, high expression of c-MET protein was observed in 3 (60.0%). The expression level of miR-34a was significantly lower in the patients with squamous cell histology (P < 0.001) and lymphatic invasion (P = 0.001). The patients expressing high level of miR-34a were significantly associated with a longer RFS (55.6 months; 95% CI, 47.83-63.36 vs 21.6 months; 95% CI, 17.42-25.82, P = 0.020, respectively) for adenocarcinoma subtype. We could not detect any correlation between the c-MET and RFS (P = 0.666), however, adenocarcinoma patients exhibiting low c-MET mRNA and high miR-34a expression had a significantly longer RFS (54.4 months; 95% CI, 44.59-64.20 vs 18.7 months; 95% CI, 8.93-28.42, P = 0.042). Likewise, although CDK6 expression was not associated with RFS (P = 0.601), the adenocarcinomas having low CDK6 mRNA and high miR-34a expression tended to be longer RFS (55.1 months; 95% CI, 46.40-67.73 vs 27.8 months; 95% CI, 23.04-32.56, P = 0.059). In univariate Cox regression analysis, the relative risk (RR) for recurrence for adenocarcinoma patients with low miR-34a expression was 8.1 (95% CI, 1.01-65.58; P = 0.049) as well as with TNM stage, LN involvement, and the presence of lymphatic invasion of 13.6 (95% CI, 2.93-62.64; P = 0.001), 4.2 (95% CI, 1.05-16.76; P = 0.043) and 7.1 (95% CI, 1.46-34.00; P = 0.015), respectively. In multivariate analysis, miR-34a retained its prognostic independency for RFS (RR, 11.5; 95% CI, 1.31-100.68; P = 0.027). Conclusions: We demonstrated the inverse correlation between miR-34a and c-MET and CDK6 in human NSCLC and their prognostic significance for RFS especially in lung adenocarcinoma. Citation Format: Ji Hyung Hong, Kang San Roh, Sung-Suk Suh, Suk Chan Lee, Jae Ho Byun, Myung ah Lee, Jin Hyoung Kang. Prognostic significance of miR-34a and its inverse correlation with c-MET and CDK6 in lung adenocarcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3131. doi:10.1158/1538-7445.AM2015-3131
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.